EULAR 2023 – Day 3 Report
Jun 02, 2023
Recent News
Read ArticleDay 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.
RA and cancer risk in the biologic era
Jun 02, 2023
A nationwide population-based study, by Beydon et al. (OP0044), has performed a more recent (2010-2020) analysis of cancer incidence in people living with RA within the French national claim database, compared to general population, measured in the French Network of Population-Based Cancer Registries.
Read Article
Unmasking Lupus Pregnancy: Adherence and Drug Monitoring Dilemmas
Jun 02, 2023
Risk of poor pregnancy outcomes in lupus patients continues to remain high, especially in the setting of high disease activity. Preliminary data from a lupus pregnancy LEGACY cohort presented at EULAR 2023 raise concern.
Read Article
AI in RA: the story grows along the patient pathway
Jun 02, 2023
The use of artificial intelligence to analyse large data sets using its subset component machine learning has taken centre stage recently in the management of rheumatic conditions, including rheumatoid arthritis. The use of AI is now starting to cross the various stages in patient care from detection, diagnosis, treatment and the prediction of long-term outcome.
Read Article
#EULAR23 – Day 1 Report
The opening Plenary session and presidential address was followed by a number of overview and review sessions with but a half-day of abstracts presentations, on several therapeutic areas including JIA, COVID and more.
https://t.co/7TayWx8SR6 https://t.co/p1K1MduPmO
Links:
Jun 02, 2023
Promising new therapies in SLE
Dr. Yuz Yusof ( @Yuz6Yusof ) weighs in.
The pharmacology treatment in SLE is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians.
https://t.co/0G6EMYp2mb https://t.co/Yc31sR4fRE
Links:
Jun 02, 2023
An update on JAK inhibitors and cardiovascular risks
Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors.
https://t.co/yZqHEg73bn https://t.co/CzVH62LEgL
Links:
Jun 02, 2023
RheumNow Eular 2023 Daily Recap Series https://t.co/oZXuyv8wL5
Jun 02, 2023
The key data for treating clinically suspect arthralgias (CSA):
TREAT-EARLIER (MTX)
ARIAA, APIPPRA (abatacept)
but what we need to do going forward:
stratify pts better for studies
predict individual risk better, to weight up risk-benefit of intervention
#EULAR2023 @RheumNow https://t.co/h3gNIyLxPY
Jun 02, 2023
Key arguments for CSA skeptics:
- definitions, imaging aren’t anywhere near as good as our own suspicion as clinicians is
- we still struggle to prevent RA
- it’s easy to go down a therapeutic slippery slope, and hard to track back
- labels are hard to remove
#EULAR2023 @RheumNow https://t.co/4adop3IR8g
Jun 02, 2023
Presenting work to improve referrals from primary care, reducing delays in diagnosis in rheumatic conditions. Sharing the set up of Rheumatology Academy and Collaborative Network (RheumACaN) and the impact it is making @RBNHSFT @NASSexercise @RheumatologyUK @RheumNow #EULAR2023 https://t.co/v0BBRiFtEy
Jun 02, 2023
Check out RheumNow's #EULAR23 coverage!
https://t.co/rGBWF0lx4g https://t.co/6SEon6poi4
Links:
Jun 02, 2023
RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
Jun 02, 2023
RheumNow Eular 2023 Daily Recap Series https://t.co/ScW9jWvzl9
Jun 02, 2023
So Annette van der Helm-van Mil makes some clear arguments about why CSA is real. But Filip Van den Bosch gives his disclosure: the clinical rheumatologist’s inherent skepticism of ‘early disease’
#EULAR2023 @RheumNow https://t.co/GbaBhQE5AB
Jun 02, 2023
ILD in RA and PsA
@AurelieRheumo discusses inconsistent data inconsistent data have proposed on the effect of bio/tsDMARDs on the risk of ILD.
ILD is a severe extra articular manifestation of RA, with limited treatment strategies and poor prognosis.
https://t.co/U1RjvgTCL8 https://t.co/qmxXBTK05N
Links:
Jun 02, 2023
Using app for self-management in clinical care. There is a need to have continued engagement both patients and clinicians, constantly evolve the product, adapt to the changing needs of patients eg.pre and post pandemic, #WIIFM? @AurelieRheumo @ProfYelizPrior #EULAR2023 @RheumNow https://t.co/5RKog9EMsV
Jun 02, 2023
Metabolic Burden in the Early Stages of PsA
Dr. Aurelie Najm ( @AurelieRheumo )discusses abstract OP0066 presented at EULAR 2023 in Milan, Italy.
https://t.co/Z39ibke3JD https://t.co/YvWbNz9tFH
Links:
Jun 02, 2023
The #EULAR2023 wall is growing..@RheumNow https://t.co/tpJSp5Yc9X
Jun 02, 2023
Very interesting.
Overweight fibromyalgia pts had some sustained benefit of their fibro on a very low calorie ketogenic diet (8 weeks ketogenic, 12 weeks carb reintroduce)
Pain improvements matched weight loss. Many questions, I want to see more!
POS1339 #EULAR2023 @RheumNow https://t.co/3rIPmSVUwj
Jun 02, 2023
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Jun 02, 2023
From the blog
ICYMI: The Biosimilar "Buy In"
May 29, 2023
The landscape of biosimilars is vast. This year alone we are expecting 17 biosimilars in rheumatology. While some pharmaceutical company and payer contracts are still under negotiation, we need to start preparing ourselves and our patients.
Drs. Jack Cush and Arthur Kavanuagh shared insights into these key discussions during RheumNow Live 2023.
Read Post
Podcasts
TNR- Rheumatoid Arthritis - Decisive TherapeuticsMay 31, 2023
3 - 4-5 Rule (5.26.2023)May 26, 2023
TNR- Spondyloarthritis InnovationsMay 24, 2023
Therapeutic Updates
Mechanism of Action of an Interleukin (IL)–23 Inhibitor Monoclonal Antibody in Moderate to Severe Plaque Psoriasis and Active Psoriatic Arthritis
Sponsored by Janssen Biotech, Inc.
Jun 01, 2023
This disease education update from Janssen provides an overview of an interleukin (IL)-23 inhibitor.
Read Post
